Castle Biosciences (CSTL)

• Market cap: $721M
• 1 day: -1.53%
• 5 days: -7.21%
• 1 month: -3.63%
• 3 months: -10.84%
• 6 months: -7.54%
• Year to date: -8.17%
• 1 year: 4.29%
• 5 years: -20.55%
• 10 years: 20.33%
• Sector: Healthcare
• Industry: Medical Laboratories

About: Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others.

Employees: 710

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

272% more call options, than puts

Call options by funds: $3.7M | Put options by funds: $996K

46% more first-time investments, than exits

New positions opened: 38 | Existing positions closed: 26

4% more funds holding

Funds holding: 184 [Q3] → 192 (+8) [Q4]

5% more repeat investments, than reductions

Existing positions increased: 66 | Existing positions reduced: 63

0.88% more ownership

Funds ownership: 93.09% [Q3] → 93.97% (+0.88%) [Q4]

5% less capital invested

Capital invested by funds: $737M [Q3] → $701M (-$35.4M) [Q4]

50% less funds holding in top 10

Funds holding in top 10: 4 [Q3] → 2 (-2) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $41 59% upside
• Avg. target: $41 59% upside
• High target: $41 59% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Stephens & Co. Mason Carrico 40% 1-year accuracy 8 / 20 met price target

59% upside $41

Overweight Reiterated

2 Jan 2025